Mark Dickson, MD

Memorial Sloan Kettering Cancer Center
New York, New York, United States

Disclosure information not submitted.

Presentation(s):

• Debate #1: SHOULD WE TRY TO PREVENT DRUG RESISTANCE THROUGH EARLIER COMBINATION TREATMENT OR STEER AND TARGET DRUG RESISTANCE WHEN IT DEVELOPS?

  Thursday, November 14, 2024
  11:30 AM – 12:15 PM PST

• Paper 45 - A PHASE II STUDY OF PALBOCICLIB COMBINED WITH THE PD-1 INHIBITOR RETIFANLIMAB IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Debate #2: HYPOFRACTIONATED REGIMENS CAN BE USED AS A STANDARD OF CARE FOR PREOPERATIVE RADIOTHERAPY FOR STS WITHOUT A PHASE 3 TRIAL

  Friday, November 15, 2024
  10:30 AM – 11:15 AM PST

• Paper 81 - PEMBROLIZUMAB, RADIOTHERAPY, & SURGERY VS RADIOTHERAPY & SURGERY FOR STAGE III SOFT TISSUE SARCOMA OF THE EXTREMITY: OUTCOMES & SARCOMA IMMUNE CLASS ANALYSIS IN SU2C-SARC032 RANDOMIZED CLINICAL TRIAL

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST

• Paper 89 - PERIPHERAL BLOOD T CELL PHENOTYPE AND TUMOR MICROENVIRONMENT SUBTYPE ARE INDEPENDENTLY ASSOCIATED WITH IMMUNE CHECKPOINT BLOCKADE OUTCOMES IN SARCOMAS

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST